EGFR and non-small cell lung carcinoma: The plasma levels of circZNF91 could distinguish the gefitinib-sensitive group from the resistant group (AUC = 0.8054) and were associated with better progression-free survival in NSCLC patients treated with this EGFR inhibitor.